Business Context and Reporting Period
This Form 8-K is filed by pSivida Corp. (not Eyepoint, Inc.) on December 23, 2010. The report addresses a significant regulatory event concerning the company's collaborative partner, Alimera Sciences, Inc., regarding the drug candidate Iluvien for the treatment of diabetic macular edema.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The primary material event reported is that Alimera Sciences, Inc. received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Iluvien. This indicates the FDA has not approved the application in its current form and requires further action or information.
Guidance, Outlook, and Risks
- Regulatory Risk: The Complete Response Letter represents a significant regulatory hurdle for the Iluvien program.
- Management Commentary: The filing references a press release (Exhibit 99.1) for full details but does not include specific management commentary or revised financial guidance within the text of this 8-K.
- Unusual Items: The receipt of the FDA letter is the sole unusual item disclosed in this report.
Investor Verification Checklist
- Review the full text of the press release filed as Exhibit 99.1 for specific details on the FDA's requirements.
- Verify the impact of the Complete Response Letter on the commercial timeline for Iluvien.
- Confirm the nature of the collaboration agreement between pSivida Corp. and Alimera Sciences, Inc. to understand financial implications.
- Check subsequent filings for updates on the resubmission of the NDA or further FDA communications.